Validating The BLEO-Induced Mouse Model For Drug Discovery

Idiopathic pulmonary fibrosis (IPF) is a devastating disease characterized by progressive scarring of the lungs, which severely impairs lung function over time. Developing effective treatments for IPF has been a challenge for the medical community, as the mechanisms driving this disease are complex and not fully understood. To accelerate drug discovery, animal models that closely mimic the human disease are crucial. In this context, a recent study by Petersen et al (2024) has made significant strides in validating a well-known IPF mouse model of bleomycin (BLEO) induced Pulmonary Fibrosis and demonstrating its effectiveness in evaluating potential therapies, particularly through the use of advanced lung function testing systems like the vivoFlow and flexiVent.